叶鹏
药学
党委组织部副部长、副教授、副主任药师、硕士生导师
党委组织部副部长、副教授、副主任药师、硕士生导师
导师介绍
| 姓名 | 叶鹏 |
| 出生年月 | 1980年1月 |
| 单位 | 武汉大学人民医院药学部 |
| 所属学科 | 药学 |
| 职务、职称及头衔 | 党委组织部副部长、副教授、副主任药师、硕士生导师 |
| yp800111@163.com | |
| 联系方式 | 027-88041911转86448或18971099926 |
| 研究方向 |
1.药物靶向递送系统研究 2.抗氧化天然产物活性研究 |
| 个人简介 | |
| 主要从事药物靶向传递和抗氧化天然产物活性研究，发表学术论文20余篇，其中SCI二区论文10篇，包括一区TOP1篇，二区TOP2篇，主持国家自然科学基金、湖北省自然科学基金、武汉大学自主科研项目、武汉大学抗衰老基金项目，以骨干身份参与国家重点研发计划、国家卫生健康委干细胞临床研究项目、湖北省重点研发计划的研究，以第二参与人参与国家自然科学基金项目2项，研究成果获湖北省科技进步二等奖。 | |
| 学术任职与荣誉 | |
| 湖北省肝胆疾病学会第一届青年委员会委员 | |
| 教育履历 | |
|
1998.09-2002.06 武汉大学药学院药学专业获学士学位 2007.09-2009.06 武汉大学药学院药剂学专业获硕士学位 2010.09-2014.06 华中科技大学同济医学院药学院药理学专业获博士学位 |
|
| 工作履历 | |
|
2002.07-2008.11 武汉大学人民医院药学部药师 2008.11-2016.11 武汉大学人民医院药学部主管药师 2016.11-至今 武汉大学人民医院药学部副主任药师 2016.11-2018.12 武汉大学人民医院科教处副处长 2018.12-2019.03 武汉大学人民医院党委组织部副部长 2019.04-2021.12 武汉大学人民医院党委组织部副部长、泌外与器官移植科党总支书记 2021.12-至今 武汉大学人民医院党委组织部副部长、医职院区分党委副书记（主持工作） |
|
| 成果获奖 | |
| 丙氨酰谷氨酰胺原料药及注射液制备的关键技术，湖北省人民政府科技进步奖二等奖，2018J-214-2-086-069-R05 | |
| 代表性论著 | |
|
1.Yang T, Li B, Qi S, Liu Y, Gai Y, Ye P, Yang G,
Zhang W, Zhang P, He X, Li W, Zhang Z, Xiang G, Xu C. Co-delivery of
doxorubicin and Bmi1 siRNA by folate receptor targeted liposomes exhibits
enhanced anti-tumor effects in vitro and in vivo. Theranostics. 2014 Aug
24;4(11):1096-111. 2.Miao Lu, Wendian Zhang, Yongkang Gai, Tan Yang, Peng Ye, Guang Yang,Xiang Ma* and Guangya Xiang，Folate–PEG functionalized silica CdTe quantum dots as fluorescent probes for cancer cell imaging，New Journal of Chemistry, 2014,38:4519-4526. 3.Ye P, Zhang W, Yang T, Lu Y, Lu M, Gai Y, Ma X, Xiang G. Folate receptor-targeted liposomes enhanced the antitumor potency of imatinib through the combination of active targeting and molecular targeting. Int J Nanomedicine. 2014 May 7;9:2167-78. 4.Huang Y, Yang T, Zhang W, Lu Y, Ye P, Yang G, Li B, Qi S, Liu Y, He X, Lee RJ, Xu C, Xiang G. A novel hydrolysis-resistant lipophilic folate derivative enables stable delivery of targeted liposomes in vivo. Int J Nanomedicine. 2014 Sep 29;9:4581-95. 5.Zhang W, Peng F, Zhou T, Huang Y, Zhang L, Ye P, Lu M, Yang G, Gai Y, Yang T, Ma X, Xiang G. Targeted delivery of chemically modified anti-miR-221 to hepatocellular carcinoma with negatively charged liposomes. Int J Nanomedicine. 2015 Jul 29;10:4825-36. 6.Chen Y, Cheng Y, Zhao P, Zhang S, Li M, He C, Zhang X, Yang T, Yan R, Ye P, Ma X, Xiang G. Co-delivery of doxorubicin and imatinib by pH sensitive cleavable PEGylated nanoliposomes with folate-mediated targeting to overcome multidrug resistance. Int J Pharm. 2018 May 5;542(1-2):266-279. 7.Ye P, Li WL, Bao LT, Ke W. Mulberrin Confers Protection against Doxorubicin-Induced Cardiotoxicity via Regulating AKT Signaling Pathways in Mice. Oxid Med Cell Longev. 2022 Jul 7;2022:2967142. |
| Name | Peng Ye |
| Date of birth | Jan，1980 |
| Department | Department of Pharmacy, Renmin Hospital, Wuhan University |
| Title | Associate Professor, Associate Chief pharmacist, Tutor of Master degree candidate |
| yp800111@163.com | |
| TEL | 027-88041911-86448 or 18971099926 |
| Research Direction | |
|
1. Drug targeting delivery system 2.The activity antioxidant natural products |
|
| Personal Profile | |
| Mainly engaged in the research of drug targeting delivery systems and the activity of antioxidant natural product. Published more than 20 academic papers, including 10 SCI papers. Presided 4 research projects including National Natural Science Foundation of China and Natural Science Foundation of Hubei Province. Participated in the research of the National key research and development Plan, the stem cell clinical research project of the National Health Commission and the key research and development Plan of Hubei Province as the backbone. Won the second prize of Science & Technology Progress Award of Hubei Province. | |
| Selected Publications | |
|
1.Yang T, Li B, Qi S, Liu Y, Gai Y, Ye P, Yang
G, Zhang W, Zhang P, He X, Li W, Zhang Z, Xiang G, Xu C. Co-delivery of
doxorubicin and Bmi1 siRNA by folate receptor targeted liposomes exhibits
enhanced anti-tumor effects in vitro and in vivo. Theranostics. 2014 Aug
24;4(11):1096-111. 2.Miao Lu, Wendian Zhang, Yongkang Gai, Tan Yang, Peng Ye, Guang Yang,Xiang Ma* and Guangya Xiang，Folate–PEG functionalized silica CdTe quantum dots as fluorescent probes for cancer cell imaging，New Journal of Chemistry, 2014,38:4519-4526. 3.Ye P, Zhang W, Yang T, Lu Y, Lu M, Gai Y, Ma X, Xiang G. Folate receptor-targeted liposomes enhanced the antitumor potency of imatinib through the combination of active targeting and molecular targeting. Int J Nanomedicine. 2014 May 7;9:2167-78. 4.Huang Y, Yang T, Zhang W, Lu Y, Ye P, Yang G, Li B, Qi S, Liu Y, He X, Lee RJ, Xu C, Xiang G. A novel hydrolysis-resistant lipophilic folate derivative enables stable delivery of targeted liposomes in vivo. Int J Nanomedicine. 2014 Sep 29;9:4581-95. 5.Zhang W, Peng F, Zhou T, Huang Y, Zhang L, Ye P, Lu M, Yang G, Gai Y, Yang T, Ma X, Xiang G. Targeted delivery of chemically modified anti-miR-221 to hepatocellular carcinoma with negatively charged liposomes. Int J Nanomedicine. 2015 Jul 29;10:4825-36. 6.Chen Y, Cheng Y, Zhao P, Zhang S, Li M, He C, Zhang X, Yang T, Yan R, Ye P, Ma X, Xiang G. Co-delivery of doxorubicin and imatinib by pH sensitive cleavable PEGylated nanoliposomes with folate-mediated targeting to overcome multidrug resistance. Int J Pharm. 2018 May 5;542(1-2):266-279. 7.Ye P, Li WL, Bao LT, Ke W. Mulberrin Confers Protection against Doxorubicin-Induced Cardiotoxicity via Regulating AKT Signaling Pathways in Mice. Oxid Med Cell Longev. 2022 Jul 7;2022:2967142. |
武汉大学人民医院
湖北省人民医院